Literature DB >> 24315858

Mechanism of cleavage of alpha-synuclein by the 20S proteasome and modulation of its degradation by the RedOx state of the N-terminal methionines.

Beatriz Alvarez-Castelao1, Marc Goethals2, Joël Vandekerckhove2, José G Castaño3.   

Abstract

Alpha-synuclein is a small protein implicated in the pathophysiology of Parkinson's disease (PD). We have investigated the mechanism of cleavage of alpha-synuclein by the 20S proteasome. Alpha-synuclein interacts with the C8 (α7) subunit of the proteasome. The N-terminal part of alpha-synuclein (amino acids 1-60) is essential for its proteasomal degradation and analysis of peptides released from proteasomal digestion allows concluding that initial cleavages occur within the N-terminal region of the molecule. Aggregated alpha-synucleins are also degraded by the proteasome with a reduced rate, likely due to Met oxidation. In fact, mild oxidation of alpha-synuclein with H2O2 resulted in the inhibition of its degradation by the proteasome, mainly due to oxidation of Met 1 and 5 of alpha-synuclein. The inhibition was reversed by treatment of the oxidized protein with methionine sulfoxide reductases (MsrA plus MsrB). Similarly, treatment with H2O2 of N2A cells transfected with alpha-synuclein resulted in the inhibition of its degradation that was also reverted by co-transfection of MsrA plus MsrB. These results clearly indicate that oxidative stress, a common feature of PD and other synucleinopathies, promotes a RedOx change in the proteostasis of alpha-synuclein due to Met oxidation and reduced proteasomal degradation; compromised reversion of those oxidative changes would result in the accumulation of oxidative damaged alpha-synuclein likely contributing to the pathogenesis of PD.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Alpha-synuclein; MsrA and B; Parkinson's disease; Proteasome; Protein degradation; RedOx

Mesh:

Substances:

Year:  2013        PMID: 24315858     DOI: 10.1016/j.bbamcr.2013.11.018

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  22 in total

Review 1.  α-Synuclein in Parkinson's disease: causal or bystander?

Authors:  Peter Riederer; Daniela Berg; Nicolas Casadei; Fubo Cheng; Joseph Classen; Christian Dresel; Wolfgang Jost; Rejko Krüger; Thomas Müller; Heinz Reichmann; Olaf Rieß; Alexander Storch; Sabrina Strobel; Thilo van Eimeren; Hans-Ullrich Völker; Jürgen Winkler; Konstanze F Winklhofer; Ullrich Wüllner; Friederike Zunke; Camelia-Maria Monoranu
Journal:  J Neural Transm (Vienna)       Date:  2019-06-25       Impact factor: 3.575

2.  Peptidomimetics Based on C-Terminus of Blm10 Stimulate Human 20S Proteasome Activity and Promote Degradation of Proteins.

Authors:  Katarzyna Cekała; Karolina Trepczyk; Daria Sowik; Przemysław Karpowicz; Artur Giełdoń; Julia Witkowska; Małgorzata Giżyńska; Elżbieta Jankowska; Ewa Wieczerzak
Journal:  Biomolecules       Date:  2022-06-02

3.  Overexpression of alpha-synuclein at non-toxic levels increases dopaminergic cell death induced by copper exposure via modulation of protein degradation pathways.

Authors:  Annadurai Anandhan; Humberto Rodriguez-Rocha; Iryna Bohovych; Amy M Griggs; Laura Zavala-Flores; Elsa M Reyes-Reyes; Javier Seravalli; Lia A Stanciu; Jaekwon Lee; Jean-Christophe Rochet; Oleh Khalimonchuk; Rodrigo Franco
Journal:  Neurobiol Dis       Date:  2014-12-08       Impact factor: 5.996

4.  A de novo compound targeting α-synuclein improves deficits in models of Parkinson's disease.

Authors:  Wolfgang Wrasidlo; Igor F Tsigelny; Diana L Price; Garima Dutta; Edward Rockenstein; Thomas C Schwarz; Karin Ledolter; Douglas Bonhaus; Amy Paulino; Simona Eleuteri; Åge A Skjevik; Valentina L Kouznetsova; Brian Spencer; Paula Desplats; Tania Gonzalez-Ruelas; Margarita Trejo-Morales; Cassia R Overk; Stefan Winter; Chunni Zhu; Marie-Francoise Chesselet; Dieter Meier; Herbert Moessler; Robert Konrat; Eliezer Masliah
Journal:  Brain       Date:  2016-09-27       Impact factor: 13.501

5.  Small Molecule Modulation of Proteasome Assembly.

Authors:  Evert Njomen; Pawel A Osmulski; Corey L Jones; Maria Gaczynska; Jetze J Tepe
Journal:  Biochemistry       Date:  2018-06-27       Impact factor: 3.162

Review 6.  Methamphetamine-induced dopaminergic neurotoxicity as a model of Parkinson's disease.

Authors:  Eun-Joo Shin; Ji Hoon Jeong; Yeonggwang Hwang; Naveen Sharma; Duy-Khanh Dang; Bao-Trong Nguyen; Seung-Yeol Nah; Choon-Gon Jang; Guoying Bing; Toshitaka Nabeshima; Hyoung-Chun Kim
Journal:  Arch Pharm Res       Date:  2021-07-20       Impact factor: 4.946

7.  Irisflorentin improves α-synuclein accumulation and attenuates 6-OHDA-induced dopaminergic neuron degeneration, implication for Parkinson's disease therapy.

Authors:  Yue-Mi Chen; Shih-Ping Liu; Hsin-Lien Lin; Ming-Chia Chan; Yen-Chuan Chen; Yu-Ling Huang; Min-Chen Tsai; Ru-Huei Fu
Journal:  Biomedicine (Taipei)       Date:  2015-02-02

8.  Generation of SNCA Cell Models Using Zinc Finger Nuclease (ZFN) Technology for Efficient High-Throughput Drug Screening.

Authors:  Warunee Dansithong; Sharan Paul; Daniel R Scoles; Stefan M Pulst; Duong P Huynh
Journal:  PLoS One       Date:  2015-08-28       Impact factor: 3.240

Review 9.  Alpha-synuclein research: defining strategic moves in the battle against Parkinson's disease.

Authors:  Luis M A Oliveira; Thomas Gasser; Robert Edwards; Markus Zweckstetter; Ronald Melki; Leonidas Stefanis; Hilal A Lashuel; David Sulzer; Kostas Vekrellis; Glenda M Halliday; Julianna J Tomlinson; Michael Schlossmacher; Poul Henning Jensen; Julia Schulze-Hentrich; Olaf Riess; Warren D Hirst; Omar El-Agnaf; Brit Mollenhauer; Peter Lansbury; Tiago F Outeiro
Journal:  NPJ Parkinsons Dis       Date:  2021-07-26

10.  Epitope Mapping of Antibodies to Alpha-Synuclein in LRRK2 Mutation Carriers, Idiopathic Parkinson Disease Patients, and Healthy Controls.

Authors:  Beatriz Alvarez-Castelao; Ana Gorostidi; Javier Ruíz-Martínez; Adolfo López de Munain; José G Castaño
Journal:  Front Aging Neurosci       Date:  2014-07-15       Impact factor: 5.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.